Clinical Isolates of Acinetobacter spp. Are Highly Serum Resistant Despite Efficient Recognition by the Complement...

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Acinetobacter species are critical Gram-negative pathogens causing severe hospital-acquired infections, particularly in vulnerable populations.
• Increasing multi- and extensively drug-resistant (MDR/XDR) strains of Acinetobacter pose a significant global health threat.
• The complement system is a crucial innate immune defense against microbial invasion, making understanding Acinetobacter's evasion strategies vital.

Purpose of the Study:

• To investigate the interaction between clinical isolates of Acinetobacter spp. and the human complement system.
• To characterize the mechanisms by which Acinetobacter evades complement-mediated killing.
• To determine the role of the bacterial capsule in Acinetobacter's resistance to complement.

Main Methods:

• Incubation of 50 clinical Acinetobacter isolates with human serum and whole blood.
• Flow cytometry to detect bacterial recognition by human IgG, IgM, and complement components (C1q, C4b, C3b, C5b).
• India ink staining and capsule mutant analysis to assess the role of capsular polysaccharides.

Main Results:

• Most Acinetobacter isolates demonstrated high survival rates in serum and whole blood, indicating significant serum resistance.
• Complement components C3b were deposited on most isolates, but C5b and membrane attack complex (MAC) formation were largely absent, preventing lysis.
• Capsular polysaccharide production was identified as a key mechanism for preventing MAC deposition and lysis, mediating resistance to complement-mediated bactericidal activity.

Conclusions:

• Clinical Acinetobacter isolates exhibit remarkable resistance to complement-mediated killing, despite efficient recognition by early complement components.
• The bacterial capsule plays a critical role in inhibiting terminal complement pathway activation and preventing complement-dependent bacterial lysis.
• Understanding these evasion mechanisms is essential for developing novel therapeutic strategies against Acinetobacter infections.